Elsevier’s Oncology Journal Network highlights

Explore the latest breakthroughs shaping cancer research and clinical care with Elsevier’s Oncology Journal Network highlights. Bringing together insights from leading peer-reviewed oncology journals, this collection showcases cutting-edge studies, emerging therapies, and expert perspectives across the cancer continuum—from prevention and diagnosis to treatment and survivorship. Designed for researchers, clinicians, and healthcare professionals, it offers a curated view of high-impact oncology research driving innovation and improving patient outcomes worldwide.

Melanoma Awareness Month

• Carbon-Ion Radiotherapy for Head and Neck Mucosal Melanoma: Preliminary Clinical Outcomes and the MedAustron Approach for Reporting RBE-Weighted Dose With 2 Modelsopens in new tab/window

• PTCOG Ocular Survey – Perspective on Ocular Particle Therapy: Current Practices and Emerging Trendsopens in new tab/window

• Immunotherapy for anorectal melanoma: A case report - ScienceDirectopens in new tab/window

• Cutaneous toxicity following intra-arterial chemotherapy with melphalan for uveal melanoma: A case reportopens in new tab/window

• Unusual presentation and course of malignant melanoma of anal canal in an African-American patientopens in new tab/window

• S-adenosylmethionine blocks tumorigenesis and with immune checkpoint inhibitor enhances anti-cancer efficacy against BRAF mutant and wildtype melanomasopens in new tab/window

• Tozasertib activates anti-tumor immunity through decreasing regulatory T cells in melanomaopens in new tab/window

• Acral melanoma: new insights into the immune and genomic landscape - ScienceDirectopens in new tab/window

• Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerationsopens in new tab/window

• Corresponding ctDNA and tumor burden dynamics in metastatic melanoma patients on systemic treatmentopens in new tab/window

• Peroxisome proliferator-activated receptors: Key regulators of tumor progression and growthopens in new tab/window

• The role of coenzyme Q10 as a preventive and therapeutic agent for the treatment of cancersopens in new tab/window

• Gamma Knife Stereotactic Radiosurgery With a Reduced Peripheral Dose: Outcomes in Uveal Melanoma Patientsopens in new tab/window

• New Findings in the Visualization of Subepithelial Melanoma or Pseudoprogression-Like Phenomena in Oral Mucosal Melanoma During Carbon-Ion Radiation Therapy opens in new tab/window

• Carbon Ion Versus Photon-based Stereotactic Ablative Radiation Therapy for Patients with Choroidal Melanomaopens in new tab/window

• Surgical Reconstruction Toxicity Following Hypofractionated Adjuvant Radiation Therapy for Primary Cutaneous Melanomaopens in new tab/window

• Staged I-125 Eye Plaque Brachytherapy for the Treatment of Large Uveal Melanoma: A Single Institution Experience opens in new tab/window

• Stereotactic Radiation Therapy or Protons for Uveal Melanoma Patients? An Artificial Intelligence (AI)-Based Clinical Treatment Decision-Making Tool Predicting Doses To Radiation Therapy Constraintsopens in new tab/window

• Synchrotron Microbeam Radiation Therapy in Combination With Gold Nanoparticles Improves Control of Mouse Melanomaopens in new tab/window

• Tirbanibulin 1 % ointment: A narrative review of new data presented at the 11th World Congress of Melanoma in conjunction with 21st European Association of Dermato-Oncology Congress 2025opens in new tab/window

• BRAF/MEK inhibitor rechallenge in patients with non-resectable or metastatic BRAF V600-mutated melanoma: A stratified, controlled, retrospective EUMelaReg multicenter studyopens in new tab/window

• CLAUDIUS Study: Risk of materno-fetal transmission of melanoma cells in pregnant women with high grade melanoma – A retrospective multicenter study and literature reviewopens in new tab/window

• Comparative analysis of progression free survival and treatment maintenance in patients with advanced melanoma responding to first-line treatmentopens in new tab/window

• Mutational landscape of oral mucosal melanoma based on comprehensive cancer genomic profiling tests in a Japanese cohortopens in new tab/window

• Twelve years after: The french national network on rare head and neck tumours (REFCOR)opens in new tab/window

• Immuno-oncology approaches to overcome T cell exhaustion in melanomaopens in new tab/window

• Deciphering the prognostic value and immunotherapeutic strategy of aggrephagy in melanoma: Integrating single-cell sequencing and machine learningopens in new tab/window

• Role of neoadjuvant pembrolizumab in advanced melanomaopens in new tab/window

• Metabolism at the core of melanoma: From bioenergetics to immune escape and beyondopens in new tab/window

• Sapogenin-based nanoscale assemblies induce immunogenic cell death, remodel the tumor microenvironment, and drive systemic antitumor immunity in melanomaopens in new tab/window

• Irreversible electroporation activates the NLRP3 inflammasome pathway mediating the antitumor immune responses in pancreatic canceropens in new tab/window

• Cancer overdiagnosis: A challenge in the era of screeningopens in new tab/window

• Chromatin assembly factor 1 suppresses epigenetic reprogramming toward adaptive drug resistanceopens in new tab/window

• Overview of skin cancer types and prevalence rates across continentsopens in new tab/window

• Survival benefits and toxicity effects of radiotherapy and immunotherapy treatments in melanoma patients with brain metastases: A meta-analysisopens in new tab/window

• State-of-the-art machine learning techniques for melanoma skin cancer detection and classification: a comprehensive reviewopens in new tab/window

Lung Cancer article collection

Cancer Letters

• Autophagy-driven regulation of cisplatin response in human cancers: Exploring molecular and cell death dynamics opens in new tab/window

• Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung canceropens in new tab/window

• The interplay between autophagy and apoptosis: its implication in lung cancer and therapeuticsopens in new tab/window

Cancer Pathogenesis and Therapy

• Epithelial–mesenchymal transition (EMT) and its role in acquired epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) chemoresistance in non-small cell lung cancer (NSCLC)opens in new tab/window

• Inflammatory cytokines and specific factors influencing lung cancer progressionopens in new tab/window

• Targeting tumor-associated neutrophils: A promising strategy in lung cancer immunotherapyopens in new tab/window

• Amide proton transfer-weighted MRI in predicting pathological types of brain metastases in lung Canceropens in new tab/window

Cancer Treatment and Research Communications

• Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief reportopens in new tab/window

• The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapyopens in new tab/window

• Personalized medicine: An alternative for cancer treatment opens in new tab/window

Chinese Medical Journal Pulmonary and Critical Care Medicine

• Mechanisms and current advances in treating KRAS-mutated lung cancer opens in new tab/window

• Temporal trends in the burden of tracheal, bronchial, and lung cancer in China and globally: A comprehensive analysis from 1990 to 2021opens in new tab/window

• Sphingolipid metabolism dysregulation: A cause for lung cancer development, progression, and resistance to therapies opens in new tab/window

• Heterogeneity and therapeutic implications of cancer-associated fibroblasts in lung cancer: Recent advances and future perspectives opens in new tab/window

Clinical Lung Cancer

• TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection opens in new tab/window

• Lung Cancer in Women: The Past, Present, and Futureopens in new tab/window

• Pembrolizumab Plus Chemotherapy Per PD-L1 Stratum In Patients With Metastatic Non–Small Cell Lung Cancer: Real-World Effectiveness Versus Trial Efficacy opens in new tab/window

• Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications opens in new tab/window

• Young Onset Lung Cancer in India: Insights Into Clinical, Demographic, and Genomic Profiles opens in new tab/window

Current Problems in Cancer: Case Reports

• Use of anamorelin hydrochloride in a patient with lung cancer-related cachexia undergoing chemoradiotherapy: A case report opens in new tab/window

• High-flow nasal cannula combined with intravenous general anesthesia for stent implantation in right lung cancer: A case report opens in new tab/window

• Rare case of de novo EGFR L718V mutation-positive non-small cell lung cancer successfully treated with afatinib opens in new tab/window

International Journal of Particle Therapy

• NTCP-Based Prediction of Lung Sparing With IMPT in BC Patients and Implication of Patient Selection opens in new tab/window

• Comprehensive Robustness Evaluation of Proton and Carbon-Ion Plans in Thoracic Cancer Treatment opens in new tab/window

• Definitive Proton Beam Therapy for Second Primary Non–small Cell Lung Cancer After Pneumonectomy opens in new tab/window

• Feasibility of Utilizing Spot-Scanning Proton Arc (SPArc) for Whole-Lung Irradiation: A Case Report opens in new tab/window

Journal of the National Cancer Center

• Cancer incidence and mortality in China, 2022 opens in new tab/window

• Immunological features of EGFR-mutant non-small cell lung cancer and clinical practice: a narrative review opens in new tab/window

• Long-term exposure to ozone and incidence of lung cancer in China: data based on a national population cohort (ChinaHEART) opens in new tab/window

Journal of Thoracic Oncology

• Lung Cancer in Jordan opens in new tab/window

• Lung Cancer in Norwayopens in new tab/window

• Lung Cancer in Tanzania opens in new tab/window

• Lung Cancer in Argentina opens in new tab/window

• Advances in Lung Cancer Basic and Translational Research in 2025 – Overview and Perspectives Focusing on NSCLCopens in new tab/window

• 50 Years of Progress in NSCLC: A New Fellow’s Guide in the Clinicopens in new tab/window

• Safety and Sample Adequacy for Comprehensive Biomarker Testing of Bronchoscopic Biopsies: An American Association of Bronchology and Interventional Pulmonology and International Association for the Study of Lung Cancer Clinical Practice Guideline opens in new tab/window

• Screening for Lung Cancer, Overdiagnosis, and Healthcare Utilization: A Nationwide Population-Based Studyopens in new tab/window

• Risk-Based Lung Cancer Screening in Clinical Practiceopens in new tab/window

• Prospective Evaluation of Lung Cancer Screening Eligibility Criteria and Lung Cancer Detection in the Yorkshire Lung Screening Trialopens in new tab/window

• Screening-Detected Versus Interval Lung Cancer in the Biennial Korean National Lung Cancer Screening Program: Proportion, Characteristics, and Mortalityopens in new tab/window

• Barriers to Lung Cancer Screening in a Multi-Disciplinary Thoracic Oncology Program Cohort: Effects of an Incidental Pulmonary Nodule Programopens in new tab/window

• Molecular Tumor Boards: A Consensus Statement From the International Association for the Study of Lung Cancer opens in new tab/window

• Low Dose Computed Tomography for Lung Cancer Screening in Tuberculosis Endemic Countries: A Systematic Review and Meta-Analysis opens in new tab/window

• Lung Cancer Screening Program Quality Indicators—Review and Recommendations: An International Association for the Study of Lung Cancer Delphi Process Studyopens in new tab/window

• Impact of Comorbidities on the Mortality Benefits of Lung Cancer Screening: A Post-Hoc Analysis of the PLCO and NLST Trials opens in new tab/window

• Predicted Effect of Incidental Pulmonary Nodule Findings on NSCLC Mortality opens in new tab/window

• Overdiagnosis of Lung Cancer Due to the Introduction of Low-Dose Computed Tomography in Average-Risk Populations in the People’s Republic of Chinaopens in new tab/window

• Recommendations for Standardization of Tobacco Use Treatment Dataopens in new tab/window

• The Use of Investigator-Assigned Subjective or Judgmental Efficacy and Toxicity Reporting in Early Phase Clinical Trials of Lung Cancer Treatments opens in new tab/window

• The International Association for the Study of Lung Cancer Staging Project: The Impact of Smoking Status on Lung Cancer Staging in the Ninth Edition of the TNM Classificationopens in new tab/window

• The Risk and Reversibility of Osimertinib-Related Cardiotoxicity in a Real-World Populationopens in new tab/window

• The 2024 International Association for the Study of Lung Cancer Global Survey on Biomarker Testingopens in new tab/window

• Current and Future Perspectives on Computed Tomography Screening for Lung Cancer: A Roadmap From 2023 to 2027 From the International Association for the Study of Lung Cancer opens in new tab/window

• Second Primary Lung Cancer – An Emerging Issue in Lung Cancer Survivorsopens in new tab/window

• Lung Cancer Oncogene-Directed Therapy, Fertility, and Pregnancyopens in new tab/window

• Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Canceropens in new tab/window

• American Radium Society Appropriate Use Criteria on Cardiac Toxicity Prevention and Management After Thoracic Radiotherapyopens in new tab/window

Lung Cancer

• Advanced-stage ALK-positive non–small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS databaseopens in new tab/window

• An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer opens in new tab/window

• Definition of resectable stage III non-small cell lung cancer: A systematic review from EORTC lung cancer group opens in new tab/window

Neoplasia

• Lung cancer lesion detection in histopathology images using graph‐based sparse PCA network opens in new tab/window

• Evidence based on Mendelian randomization: Causal relationship between mitochondrial biological function and lung cancer and its subtypesopens in new tab/window

• Dihydroartemisinin, a potential PTGS1 inhibitor, potentiated cisplatin-induced cell death in non-small cell lung cancer through activating ROS-mediated multiple signaling pathwaysopens in new tab/window

Radiation Medicine and Protection

• A meta-analysis of the diverse invasion and migration responses of lung cancer cells to photon irradiation opens in new tab/window

• A summary of UNSCEAR 2019 report on lung cancer from exposure to radon and research needs opens in new tab/window

• Regulator of G protein signaling 20 contributes to radioresistance of non-small cell lung cancer cells by suppressing pyroptosisopens in new tab/window

Seminars in Oncology

• Explainable machine learning and feature interpretation to predict survival outcomes in the treatment of lung cancer opens in new tab/window

• Chemotherapy plus immunotherapy as first line combination in older patients with extensive stage small cell lung cancer: A systematic review and meta-analysis opens in new tab/window

Seminars in Ultrasound, CT and MRI

• The Role of Chest Radiography in Lung Canceropens in new tab/window

• Imaging of Lung Cancer Staging: TNM 9 Updatesopens in new tab/window

Translational Oncology

• Systemic immune-inflammation index predicts survival in patients with resected lung invasive mucinous adenocarcinomaopens in new tab/window

• Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapiesopens in new tab/window

• Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations opens in new tab/window

1. ​BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomesopens in new tab/window

2. Enzalutamide plus Radium-223 in Metastatic Castration-Resistant Prostate Cancer: results of the EORTC 1333/PEACE-3 trial.opens in new tab/window

3. Dostarlimab and niraparib in primary advanced ovarian canceropens in new tab/window

4. Savolitinib plus osimertinib in EGFR-mutated advanced NSCLC with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH studyopens in new tab/window

5. Avelumab + sacituzumab govitecan vs avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysisopens in new tab/window

6. Enfortumab Vedotin Plus Pembrolizumab in Untreated Locally Advanced or Metastatic Urothelial Carcinoma: 2.5-Year Median Follow-Up of the Phase III EV-302/KEYNOTE-A39 Trialopens in new tab/window

7. Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyseopens in new tab/window

Elsevier’s Oncology Journal Network